Evaluating the Human Safety Net: Observational study of Physician Responses to Unsafe AI Recommendations in high-fidelity Simulation

4

- 5 Paul Festor^{1,2,*}, Myura Nagendran^{1,2,3,*}, Anthony C. Gordon^{1,3}, A. Aldo Faisal^{1,2,4,+} and
- 6 Matthieu Komorowski^{1,3,+}
- 7
 8 ¹ UKRI Centre for Doctoral Training in AI for Healthcare, Imperial College London, London,
 9 UK
- 10 ² Brain & Behavior Lab: Departments of Bioengineering and Computing, Imperial College
- 11 London, London, UK
- ³ Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London,
- 13 London, UK
- ⁴ Institute of Artificial and Auman Intelligence, Universität Bayreuth, Bayreuth, Germany
- 15 16
- 17 * Equal contribution
- 18 ⁺ These authors jointly supervised this work
- 19

20 ORCID IDs:

- 21 Paul: 0000-0002-4856-1822
 - Myura: 0000-0002-4656-5096
- 23 Tony: 0000-0002-0419-547X
- 24 Aldo: 0000-0003-0813-7207
 - Matthieu: 0000-0003-0559-5747
- 25 26

22

27 **Competing interests:**

- 28 MK has received consulting fees from Philips Healthcare, and speaker honoraria from GE 29 Healthcare. The other authors declare that no competing interests.
- 30
- 31 Open access:
- 32 For the purpose of open access and as required by funders (UKRI), the authors have
- 33 applied a Creative Commons Attribution (CC BY) licence to any 'Author Accepted
- 34 Manuscript' version arising.
- 35

36 Author contributions:

- MN, PF, MK, AG and AF conceived the study. MN and MK wrote the experimental vignettes.
 MN, PF and MK recruited participants and conducted experiments. MN post-processed the
 eye-tracking data. PF performed the initial data analysis. MN, PF, MK, AG and AF contributed
 to the subsequent interpretation of the data. PF drafted the initial version of the manuscript.
- 41 MN, PF, MK, AG and AF contributed to critical revision of the manuscript for important
- 42 intellectual content and approved the final version.
- 43

44 Funding:

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

45 This work was funded by the University of York and the Llovd's Register Foundation through the Assuring Autonomy International Programme (Project Reference 03/19/07) and supported 46 47 by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). PF and MN were supported by a PhD studentship of the UKRI Centre for Doctoral 48 49 Training in AI for Healthcare (EP/S023283/1). ACG was supported by an NIHR Research 50 Professorship (RP-2015-06-018). AAF was supported by a UKRI Turing AI Fellowship 51 (EP/V025449/1). This study/project/report is independent research funded by the NIHR 52 (Artificial Intelligence, 'Validation of a machine learning tool for optimal sepsis treatment', 53 AI AWARD01869).

54

55 Data availability:

56 The data and code (in the form of Jupyter notebooks) to reproduce the results and figures in 57 both the manuscript and the supplementary appendices are available at: 58 https://figshare.com/s/78c5ff5c6031f701c0d1

- 59
- 60
- 61

62 ABSTRACT [153 words]

In the context of Artificial Intelligence (AI)-driven decision support systems for high-stakes 63 environments, particularly in healthcare, ensuring the safety of human-Al interactions is 64 65 paramount, given the potential risks associated with erroneous AI outputs. To address this, 66 we conducted a prospective observational study involving 38 intensivists in a simulated 67 medical setting.

68 **Physicians** eve-tracking glasses received Al-generated wore and treatment recommendations, including unsafe ones. Most clinicians promptly rejected unsafe AI 69 70 recommendations, with many seeking senior assistance. Intriguingly, physicians paid 71 increased attention to unsafe AI recommendations, as indicated by eye-tracking data. 72 However, they did not rely on traditional clinical sources for validation post-Al interaction, 73 suggesting limited "debugging."

74 Our study emphasises the importance of human oversight in critical domains and highlights 75 the value of eye-tracking in evaluating human-AI dynamics. Additionally, we observed human-76 human interactions, where an experimenter played the role of a bedside nurse, influencing a 77 few physicians to accept unsafe AI recommendations. This underscores the complexity of 78 trying to predict behavioural dynamics between humans and AI in high-stakes settings.

- 79
- 80
- 81

82 INTRODUCTION

83

Artificial Intelligence (AI) driven systems are set to take an increasingly prominent supportive role in decision-making including in high-stakes settings^{1,2}. While the final decision remains in human hands, understanding how AI recommendations impact their user's behaviour is crucial. In fact, recent work has highlighted differences in our perception of human and AI advice.^{3,4} In high-risk shared decision-making settings where even non-autonomous AIdecision-support tools have surprisingly high safety assurance requirements,⁵ understanding the human-AI dynamic is key to assessing overall safety.

91

92 In this paper, we look at live safety assessment of AI for decision support in healthcare 93 because it combines many of the challenges that make AI safety assessment hard across the 94 board. Whilst AI recommendation engines have shown promising results on retrospective 95 data, the translation to the bedside has been slow due in part to concerns for patient safety.⁶ In situations where the optimal decision has historically been unclear, ^{7–9} and with technologies 96 97 like reinforcement learning that aim at recommending decisions which surpass the standard 98 of care, the safety-assessment challenge becomes even harder. One such example is 99 cardiovascular management during sepsis where the optimal personalised doses of intravenous (IV) fluids and vasopressors remain unknown.^{10,11} 100

101

102 Attempts have been made to improve the safety profile of Al-driven decision support in retrospective intensive care settings.^{12–14} Still, the necessity of prospective and higher fidelity 103 evaluations involving clinical end users is clear from recent examples in other fields.¹³ For 104 105 instance, an acute kidney injury alert system showing good performance on retrospective data 106 was found to worsen outcomes when deployed in a real-world setting, illustrating the need for 107 a careful transition between retrospective testing and prospective deployment of digital systems.¹⁵ Safely transitioning from "bytes to bedside" is a particularly complex challenge 108 because of the dynamic interaction with human users who are prone to biases and can behave 109 110 in unpredictable ways.^{16–18}

111

In response to the growing emphasis on ecologically valid testing of AI systems,^{19,20} we run 112 our behavioural experiment in a physical simulation suite, a tool which has historically been 113 114 used as a widely accepted training tool for modelling high-fidelity situations and capturing 115 patterns of human behaviour with simulation now forming a core part of medical training.²¹ 116 This immersive approach enables physicians to respond to bedside stimuli more realistically, aligning their behaviours with actual clinical practice.²² Furthermore, this shift towards a more 117 realistic setting aligns with the evolving regulatory landscape surrounding AI, which 118 119 emphasises "human-centred AI" and the holistic evaluation of human-AI team performance.^{23,24} AI safety assessment is not a mere problem of computer science but also 120 one of human-AI cooperation which should incorporate behavioural elements grounded in 121 122 human perceptual and decision-making studies.

123

We use the example of cardiovascular management in sepsis to study the behaviour of physicians in response to AI recommendations. Here, we share the results of an observational study of human-AI interaction in a high-fidelity simulation suite focusing on the influence of safe and unsafe AI recommendations on treatment decisions. Using eye-tracking as a behavioural marker, we show evidence that the attention placed by clinicians on AI recommendations, as well as broader behavioural traits such as desire for senior advice,

depends on AI advice safety. We also demonstrate that most unsafe AI recommendations
 would be appropriately rejected by the clinical team and recommend how clinical users of AI
 should be trained to further improve their robustness to bazardous AI recommendations

should be trained to further improve their robustness to hazardous AI recommendations.

134 **RESULTS**

135 We conducted an observational human-AI interaction investigation within a high-fidelity 136 simulation facility. Our primary aim was to assess clinicians' ability to detect and appropriately 137 reject unsafe AI recommendations or seek senior assistance. Participants engaged in 138 simulated patient scenarios, prescribing fluid and vasopressor doses before and after 139 receiving AI guidance, see Figure 1. The scenarios encompassed safe, unsafe, and 140 "challenged" unsafe AI recommendations, with an experimenter acting as a bedside nurse 141 trying to change the clinician's decision in the latter case. Eve-tracking technology was used 142 to monitor participants' gaze patterns during simulations. Calibration and validation 143 procedures ensured accurate gaze data collection. We divided the visual field into regions of 144 interest (ROIs) to quantify attention patterns. Physicians were recruited from an ICU, and 145 ethical approval was obtained. Data analysis was conducted using Python. The full study 146 details, including the recruitment process and ethics approval, can be found in the Methods 147 section.

148

A total of 38 intensive care physicians took part in the experiment (Figure 2). This cohort comprised 25 men (66%) and 13 women (34%), proportions in line with the national population of intensivists.²⁵ The balance between junior and senior physicians (with less or more than 5 years of experience respectively) was even and 21% of participants reported having been personally involved or having had experience, in AI research.

154

Each physician completed six (four safe, two unsafe) different patient scenarios leading to a
total of 228 recorded trials. Of these trials, 76 featured an unsafe AI recommendation and 152
were safe ones. See Supplementary Appendix D for the full trial matrix.

158

159 In total, unsafe AI recommendations were stopped more often than safe AI recommendations 160 (29% vs. 83%, p<0.0001). The proportion stopping unsafe AI recommendations rose to 92% 161 (p=0.027) when including physicians who asked for a senior opinion, which would most likely 162 lead to the unsafe AI recommendation being rejected (see Figure 3a). This analysis was further expanded by categorising physicians into junior (<5 years of intensive care unit (ICU) 163 experience) and senior (>5 years of ICU experience) practitioners. There was a non-significant 164 165 trend for junior physicians to stop AI recommendations less often than senior physicians (79%) 166 vs. 83%, n.s.). Junior physicians asked more often for a second opinion than senior physicians 167 (65% vs. 25%, p<0.0001), which led to more unsafe recommendations being stopped or escalated by juniors (94% by juniors against 91% by seniors, n.s.). 168

169

Similarly, second-opinion requests rose from 40% before seeing any AI recommendation to 57% after seeing an unsafe AI recommendation (p=0.0056) but the reduction in requests after seeing a safe AI recommendation was not significant (figure 3b). Seeing an unsafe rather than a safe AI recommendation triggered more senior/second opinion requests (57% vs. 36%, p=0.0017). Seeing unsafe AI recommendations therefore significantly increased the proportion of requests for senior help.

176

177 As expected, prior to the AI recommendation being revealed, no significant difference in gaze 178 fixations on regions of interest (ROIs) was observed between safe and unsafe scenarios 179 regarding the three AI-independent regions (ICU data chart, vital signs monitor, and patient 180 mannequin), see Figure 3c. Subsequent to the disclosure of the AI recommendation, there 181 were more fixations on the AI screen in the unsafe scenarios (mean 960) versus safe 182 scenarios (mean 700) (p=0.0015, see Figure 3d). Finally, the number of gaze fixations on the 183 Al explanation ROI was not significantly different between safe and unsafe scenarios

184

185 The distributions of initial fluid and vasopressor dose prescriptions across participants in our 186 six scenarios are shown in Figure 4. These results show wide variation in clinical practice, 187 even when given the exact same information. Figure 4 suggests that the extent of the variation 188 in prescribing might depend on case-specific features (e.g. in scenario 2, the patient had 189 already had more fluids than in scenario 1 so physicians gave less fluid, or patient 5 had sepsis 190 related to infected and leaky heart valves so physicians were more careful with both fluid and 191 vasopressor), see Supplementary Appendix E for an extended discussion.

192

193 We also investigated the extent to which AI recommendations influenced prescription 194 decisions. Physicians changed their prescription (dose of fluids and/or vasopressors) in 46% 195 (105/228) of trials after seeing what the AI suggested. Both safe and unsafe AI 196 recommendations influenced human decisions to different extents: fluid doses shifted on 197 average by 80 ml/h (and vasopressor doses by 0.01 mcg/kg/min) after a safe AI 198 recommendation compared to 40 ml/h (and 0.08 mcg/kg/min) after an unsafe AI 199 recommendation. Figure 5 shows the shift of distribution in vasopressor prescriptions before 200 and after the AI recommendation was seen for two scenarios (split by whether the entire cohort 201 is considered or only those physicians who did not ask for senior/second opinion). In scenarios 202 (such as number two) where the unsafe AI recommendation was significantly influencing, this 203 did not seem apparent when exclusively considering the physicians who did not request senior 204 help (see Supplementary Appendix F for this plot over all scenarios).

205

206 Finally, each physician had one of the two unsafe scenarios extended with a "challenge" 207 section where the bedside nurse (a member of the experimental team) was given three 208 attempts to change the physician's mind on whether or not to stop the AI recommendation 209 were it to be automatically implemented. In 95% of cases (36/38), the verbal input challenge 210 from the bedside nurse did not sway the physician's decision to accept or reject the automated 211 application of the AI recommendation. However, two participants (both junior) were persuaded 212 to change their minds from interrupting an unsafe recommendation to accepting it. Human-to-213 human interactions can therefore also play a role in the inadvertent adoption or appropriate 214 rejection of unsafe recommendations.

215 216

217 DISCUSSION

218

219 Our findings confirm that AI recommendations can influence clinician behaviour and thereby 220 impact patient care. Unsafe AI recommendations, represented here as sudden under- or over-221 dosing, were frequently (but not entirely) detected and appropriately mitigated by the clinical 222 team (by rejecting the AI recommendation). However, junior physicians more often deferred 223 the decision to senior colleagues when they were unsure about the safety of an AI

224 recommendation. This shows the importance of educating clinical teams who will interact with 225 a new AI recommender system on the correct intended use of the system, including target 226 patient population, indications, and limitations, as well as the importance of clinical context 227 when integrating the AI recommendations into their practice.

228

229 This study reinforces the call for more interdisciplinary and realistic human-AI interaction studies on domain experts.^{26,27} Critically, our experimental design also allowed us to study 230 231 human-human behavioural dynamics during an encounter with AI decision support. This is 232 important as most clinical uses of Al-driven decision support tools will be in the context of 233 multi-disciplinary teams where humans other than the final decision-maker can still positively 234 or negatively influence the interaction between the final human decision-maker and the AI. 235 This is why our study was run in a simulation suite: an environment that reproduces natural 236 stimuli of bedside practice for clinicians without any risk to patients.

237

238 While eye-tracking is typically used in controlled environments,²⁸ this study demonstrates the 239 feasibility of using this behavioural phenotypic marker of attention in more realistic, less 240 constrained, environments. Our findings indicate that physicians fixated more on unsafe than 241 safe AI recommendations implying an appropriately higher level of allocated cognitive 242 attention. However, we also observed that physicians did not rely more on AI explanations in 243 the unsafe scenarios calling into question the use of explanations as a mitigation strategy for 244 unsafe Al. Nor did physicians devote significantly more attention to looking back at the 245 'traditional' (non-AI based) clinical data after seeing an unsafe AI recommendation to 246 understand why the recommendation might be unsafe (i.e. there was no outward evidence of 247 a desire to 'debug' the unsafe AI recommendation).

248

249 The influence of AI recommendations on clinical judgement has already been studied in vignette-type experiments.³ This work goes one step closer to clinical deployment by studying 250 251 these interactions in a high-fidelity simulation environment. This setup enabled the study of 252 human-AI interaction with eye-tracking as well as the ability to investigate human-human 253 interactions as they relate to AI. Most studies of clinical decision support system safety use 254 medication error as the primary outcome measure and proxy for patient safety.²⁹ Here, we 255 look at systems that are not yet deployed in clinical practice, so measuring prescription error 256 rate directly (and correlating that to 'error' without a gold standard) is challenging. Therefore, 257 we took the problem from a different angle and aimed to estimate the ability of clinicians to 258 spot unsafe treatment recommendations from an AI tool.

259

260 However, the limitations of the study should also be acknowledged. First, as raised by many 261 physicians during the initial briefing, prescribing hourly fluid and vasopressor doses directly is 262 unusual for intensive care physicians who typically indicate blood pressure (and other 263 parameters) targets and let the bedside nurse titrate the actual doses within a reasonable 264 range to reach the set targets. Similarly, the simulation limited the physician's action space to 265 one specific aspect of patient care, preventing action plans that might go beyond the defined 266 possibilities. Moreover, making treatment decisions for the next hour is also less dynamic than 267 real clinical practice (where for example the ability to examine a real patient and use advanced 268 cardiac output monitors might add to the nuance of the overall clinical picture).

269

270 From a different perspective, one could challenge the definitions of safe and unsafe 271 recommendations used in the scenarios by arguing that there is no ground truth in sepsis

272 resuscitation and that they are therefore subjective. One might even go further and argue that strategies that under- or over-dose in specific patients (compared to the 'average') could be 273 274 desirable in some cases. The scenarios used in this experiment were designed for the unsafe 275 recommendations to be inappropriate to a majority of clinicians and validated by an 276 independent panel of intensivists. The introduction of AI-driven decision support tools, 277 particularly those using reinforcement learning aims to improve patient outcomes beyond the current standard of care.^{9,30} This means that such systems will give recommendations that 278 279 differ from what the clinical team would ordinarily have done but potentially without explanation 280 - a "mysterious oracle dilemma" where the AI oracle recommends actions that on average lead 281 to better outcomes but might occasionally be suboptimal, and the users do not get context on 282 the AI recommendation. It will therefore be essential for humans to exert critical thinking and 283 assess how reasonable the AI recommendation is to filter potentially novel but superior calls 284 by the AI from harmful recommendations.

285 As regulators push toward requiring clear intended purpose statements for software as medical devices,³¹ our high-fidelity eye-tracking based approach to evaluating an Al-driven 286 287 decision support tool serves as a basis for promoting the generation of safety evidence. 288 Furthermore, the recent rise in popularity of generative AI (most notably as large language 289 models) highlights the safety concerns of hallucinatory outputs that might be acted upon in a clinical setting and bring harm to patients.³² It is likely that an AI system that shows overall 290 291 superhuman performance in a given task will still show lower-quality performance in some 292 specific cases.³³ Solutions such as uncertainty-aware models or explainable AI might help users differentiate between well-informed recommendations and flawed calls.^{34–36} The human-293 294 Al interactions at the bedside, with a particular focus on high-pressure decision-making, would 295 also help to accelerate the safe translation of AI-based decision support tools to the bedside. 296

297

298 CONCLUSION

299

300 It is critical for clinician acceptance, regulatory compliance and real-world adoption that we 301 evaluate cooperation between clinical experts and AI decision support tools in high-fidelity 302 settings - in our case a simulated intensive care unit. This study demonstrates the influence 303 of AI recommendations on clinical behaviour and suggests that the vast majority of unsafe AI 304 recommendations are appropriately rejected by bedside clinicians. The findings on junior 305 physicians occasionally accepting an unsafe AI recommendation and their general willingness 306 to seek senior help when unsure should inform the intended use (i.e. some tools might need 307 to only be used by junior clinicians if they have access to senior advice). Uncertainty 308 awareness, novel forms of AI interpretability and a better understanding of human-human 309 interactions (i.e. team decisions) in the context of Al-driven decision support will help not only 310 with assuring safety from a regulatory perspective but also in fostering confidence and 311 approval from physician end-users.

312

313 **METHODS**

314

315 **Objective** - We conducted an observational human-AI interaction study in a high-fidelity 316 simulation facility. Our primary objective was to measure whether participants were able to 317 detect, and correctly reject, unsafe recommendations from an AI tool and/or ask for senior 318 help when appropriate. Secondary study objectives included: (i) quantifying the shift in fluid 319 and vasopressor doses induced by seeing an AI recommendation, and (ii) determining

320 whether or not gaze patterns varied differentially depending on the safety status of the AI 321 recommendation.

322

323 **Experimental design -** Participants (clinicians) were briefed on the experiment and completed 324 a pre-experiment questionnaire recording their demographics and prior experience with AI 325 (see Supplementary Appendix A for the full content of the briefing and guestionnaire). 326 Participants were told that they would conduct a review of several adult patients with sepsis 327 within a simulation suite (Imperial College Simulation Centre) and that they would need to 328 prescribe appropriate doses of fluid and vasopressor for each patient both before and after 329 getting advice from an AI tool. Critically, physicians were told that the AI recommendation 330 engine had been successfully validated in multiple retrospective settings but had not been 331 prospectively evaluated. The simulation layout is shown in Figure 1a.

332

333 Each physician completed a total of six different patient scenarios, simulating a virtual "ward 334 round". Each scenario started with physicians entering the simulation suite and conducting 335 their assessment of the patient as they saw fit. Data sources within the room included a 336 standard paper ICU bedside data chart with observations and blood results, an ICU handover 337 note including details of the patient's presentation and medical history, a vital signs monitor 338 and a physical patient mannequin (Simman 3G, Laerdal Medical, Stavanger, Norway) which 339 could be examined (see Supplementary Appendix B for the details of each patient scenario). 340 All patient scenarios were crafted by clinical experts from the authors team and to fit the needs 341 of this simulation experiment, they do not come from real patients. A member of the research 342 team played the role of the bedside ICU nurse who could only give standardised responses to 343 any questions. Following their assessment of the patient, physicians were asked to 344 recommend a dose rate for fluids (ml/hr) and vasopressors (noradrenaline, mcg/kg/min) for 345 the coming hour (to match the format of AI recommendations). Physicians rated their 346 confidence on a 1-10 scale and whether or not they would like support for their decision from 347 a senior physician (or a second opinion if the physician was already senior themselves). They 348 were then shown the AI recommendation, asked to what extent they agreed with the 349 recommendation on a 5-point Likert scale (from completely disagree to completely agree), and 350 then the initial dosing-related questions again (what dose they would prescribe, their 351 confidence level, optional ask for senior help - see figure 1b). 352

Finally, physicians were asked whether or not they would stop the AI recommendation if it were to be automatically administered to the patient. This question was intended to nuance the agreement prompt and identify situations where a participant might disagree with an AI recommendation but not necessarily consider it a threat to patient safety. Participants were clearly introduced to the nuance between these two questions in the pre-experiment briefing.

359 The running of a single patient scenario from entry into the simulation suite to exit constituted 360 one trial. Trials were categorised by the nature of the AI tool's recommendation provided to 361 the participant: safe, unsafe or "challenged" unsafe. In the latter, after the physician reported 362 whether or not they would stop the AI recommendation if it were to be automatically 363 administered, the bedside nurse was permitted three attempts (all following a standardised 364 script) to verbally try to convince them to change their mind (see Supplementary Appendix C 365 for the scripts). Each physician experienced four safe trials, one unsafe and one "challenged" 366 unsafe in a pseudo-randomised order (see the trial matrix in Supplementary Appendix D). The 367 first trial encountered by every physician was always in the safe condition to establish a

368 baseline level of trust with the AI tool and let the physician familiarise themselves with the 369 environment. The details of each patient scenario are presented in Supplementary Appendix 370 Β.

371

372 All AI recommendations were synthetically generated by the research team for the purpose of 373 ensuring a standardised experimental format (i.e. they were not from a real AI system). The 374 definition of unsafe recommendations was based on extreme under- or over-dosing of fluid 375 and/or vasopressor as per previous work.¹³ All participating physicians were fully debriefed at the conclusion of the study on the synthetic nature of the AI recommendations so as not to 376 bias their opinions of future interactions with Al-driven systems. 377

378

379 During each trial, all physician responses were recorded by a member of the research team sitting in a dead angle in the simulation suite. This data, along with questionnaire answers was 380 381 reformatted analysed Python (code here: and in available online 382 https://figshare.com/s/78c5ff5c6031f701c0d1)

383

384 Eye-tracking for gaze recording

In this study, gaze was employed as an indicator of physicians' attentional focus during 385 simulations, with particular interest in whether this varied according to the safety of the AI 386 recommendation. Pupil and first-person videos were recorded with non-invasive commercially 387 388 available eye-tracking glasses (Pupil Core headset). The Pupil Labs software (Core, version 389 3.3) utilised both eye cameras to delineate the pupil and estimate the direction of gaze within 390 the recorded field of view.

391

392 Prior to the experiment, a two-part 2D calibration procedure was conducted. The initial stage 393 involved a static calibration using five screen markers on a laptop display (default Pupil Labs 394 'screen marker' calibration). Subsequently, a depth-based static exercise was performed, 395 requiring participants to focus on nine screen markers sequentially ('natural features' mode) 396 displayed on a 60-inch TV screen, initially at 1 metre and then at 2 2-metre distance. A laptop 397 (Lenovo Thinkpad) was connected to the eye-tracking glasses for the entire experiment. To 398 allow for unrestricted movement in the suite, the glasses were connected via USB to a battery-399 powered laptop (Lenovo Thinkpad) worn by physicians in a lightweight backpack. 400

- 401 Because of variability in facial morphologies, 19/38 physicians passed the calibration 402 exercises and had their gaze-based attention data collected. Physicians were instructed to 403 point to where they were reading on the handover note at the start of each scenario as a final 404 level of validation that the eye tracking was appropriately calibrated.
- 405

We defined four key regions of interest (ROIs) (Figure 1c): the paper ICU data chart, the vital 406 407 signs monitor, the patient mannequin (Laerdal Simman 3G) and the AI display screen. Four 408 further sub-regions were identified within the AI screen ROI corresponding to four types of 409 explanation for the AI recommendation. April tags (simple QR codes) within the simulation 410 suite (see Figure 1c) were used to identify ROIs in post-processing. As is common practice in eye-tracking literature ^{37,38}, we used the number of gaze fixations per ROI—a fixation being 411 412 the predominant eye movement occurring when the foveal region of the visual field is held 413 stationary— as a proxy for participant attention.

415 Participant recruitment and simulation facility - Recruitment of ICU physicians made use of both convenience sampling and targeted advertising to a local NHS trust (Imperial College 416 417 Healthcare NHS Trust) Inclusion criteria were: (i) practising physician, (ii) has worked for two 418 or more months in an adult ICU, (iii) currently works in ICU or has worked in ICU within the 419 last 6 months. Physicians were compensated for their time and each experiment lasted 420 approximately 60 minutes. The study was approved by the Research Governance and Integrity Team (RGIT) at Imperial College London and the UK Health Research Authority (Ref: 421 422 22/HRA/1610). 423 424

425

426

428 REFERENCES

- 430 Wang G, Liu X, Ying Z, Yang G, Chen Z, Liu Z, et al. Optimized glycemic control of type 1. 431 2 diabetes with reinforcement learning: a proof-of-concept trial. Nat Med. 2023 Sep 432 14:1-10.
- 433 2. Zhan X, Xu H, Zhang Y, Zhu X, Yin H, Zheng Y. DeepThermal: Combustion 434 Optimization for Thermal Power Generating Units Using Offline Reinforcement 435 Learning, Proc AAAI Conf Artif Intell, 2022 Jun 28:36(4):4680-8.
- Nagendran M, Festor P, Komorowski M, Gordon A, Faisal AA. Quantifying the impact 436 3. 437 of AI recommendations with explanations on prescription decision making: an 438 interactive vignette study [Internet]. 2023 [cited 2023 Jun 19]. Available from: 439 https://www.researchsguare.com
- 440 4. Köbis N, Bonnefon JF, Rahwan I. Bad machines corrupt good morals. Nat Hum Behav. 441 2021 Jun;5(6):679-85.
- 442 5. Festor P, Habli I, Jia Y, Gordon A, Faisal AA, Komorowski M. Levels of Autonomy and 443 Safety Assurance for Al-Based Clinical Decision Systems. In Springer: 2021, p. 291–6.
- 444 6. van de Sande D, van Genderen ME, Huiskens J, Gommers D, van Bommel J. Moving 445 from bytes to bedside: a systematic review on the use of artificial intelligence in the 446 intensive care unit. Intensive Care Med. 2021;1-11.
- 447 7. Tejedor M, Woldaregay AZ, Godtliebsen F. Reinforcement learning application in 448 diabetes blood glucose control: A systematic review. Artif Intell Med. 2020 Apr 1;104:101836. 449
- 450 8. Prasad N, Cheng LF, Chivers C, Draugelis M, Engelhardt BE. A Reinforcement 451 Learning Approach to Weaning of Mechanical Ventilation in Intensive Care Units 452 [Internet]. arXiv; 2017 [cited 2023 Jan 6]. Available from: 453 http://arxiv.org/abs/1704.06300
- 454 Komorowski M, Celi LA, Badawi O, Gordon AC, Faisal AA. The artificial intelligence 9. 455 clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med. 456 2018;24(11):1716-20.
- 457 Yealy DM, Mohr NM, Shapiro NI, Venkatesh A, Jones AE, Self WH. Early Care of 10. 458 Adults With Suspected Sepsis in the Emergency Department and Out-of-Hospital 459 Environment: A Consensus-Based Task Force Report. Ann Emerg Med. 2021;
- 460 11. van der Ven W, Schuurmans J, Schenk J, Roerhorst S, Cherpanath T, Lagrand W, et 461 al. Monitoring, management, and outcome of hypotension in Intensive Care Unit 462 patients, an international survey of the European Society of Intensive Care Medicine. J 463 Crit Care. 2022;67:118-25.
- 12. Jia Y, Burden J, Lawton T, Habli I. Safe reinforcement learning for sepsis treatment. In: 464 465 2020 IEEE International conference on healthcare informatics (ICHI). IEEE; 2020, p. 1-466 7.
- 467 13. Festor P, Jia Y, Gordon AC, Faisal AA, Habli I, Komorowski M. Assuring the safety of 468 Al-based clinical decision support systems: a case study of the Al Clinician for sepsis 469 treatment. BMJ Health Care Inform. 2022:
- 470 14. Peng X, Ding Y, Wihl D, Gottesman O, Komorowski M, Lehman L wei H, et al. 471 Improving sepsis treatment strategies by combining deep and kernel-based 472 reinforcement learning. In American Medical Informatics Association; 2018. p. 887. 473 Available from:
- 474 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371300/pdf/2975959.pdf
- 475 15. Wilson FP, Martin M, Yamamoto Y, Partridge C, Moreira E, Arora T, et al. Electronic 476 health record alerts for acute kidney injury: multicenter, randomized clinical trial. BMJ. 477 2021 Jan 18;372:m4786.
- 478 16. Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive biases associated with 479 medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016 Nov 480 3:16(1):138.
- 17. Sujan M, Furniss D, Grundy K, Grundy H, Nelson D, Elliott M, et al. Human factors 481

482 challenges for the safe use of artificial intelligence in patient care. BMJ Health Care 483 Inform [Internet]. 2019;26(1). Available from: 484 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252977/ 485 18. Dawson NV. Arkes HR. Systematic errors in medical decision making: judgment limitations. J Gen Intern Med. 1987:2(3):183-7. 486 487 19. Quinan PS, Padilla LM, Creem-Regehr SH, Meyer M. Towards ecological validity in 488 evaluating uncertainty. In: Proceedings of Workshop on Visualization for Decision 489 Making Under Uncertainty (VIS'15) http://vdl sci utah 490 edu/publications/2015 vdmu ecologicalvalidity [Internet]. 2015 [cited 2023 Sep 29]. 491 Available from: https://miriah.github.io/publications/eco-validity-vdmu.pdf 492 20. Madras D. Pitassi T. Zemel R. Predict responsibly: improving fairness and accuracy by 493 learning to defer. Adv Neural Inf Process Syst. 2018;31. 494 21. Cato DL, Murray M. Use of Simulation Training in the Intensive Care Unit. Crit Care 495 Nurs Q. 2010 Mar;33(1):44. 496 22. Chang M, Büchel D, Reinecke K, Lehmann T, Baumeister J. Ecological validity in 497 exercise neuroscience research: A systematic investigation. Eur J Neurosci. 2022 498 Jan:55(2):487-509. 499 23. Article 8 [Internet]. Artificial Intelligence Act. [cited 2023 Sep 29]. Available from: 500 https://artificialintelligenceact.com/title-iii/chapter-2/article-8/ 501 24. Software and AI as a Medical Device Change Programme [Internet]. GOV.UK. 2023 502 [cited 2023 Oct 2]. Available from: 503 https://www.gov.uk/government/publications/software-and-ai-as-a-medical-device-504 change-programme 25. Women in Intensive Care Medicine | The Faculty of Intensive Care Medicine [Internet]. 505 506 [cited 2023 Jan 4]. Available from: 507 https://www.ficm.ac.uk/careersworkforceworkforce/women-in-intensive-care-medicine 508 26. Xu W, Dainoff MJ, Ge L, Gao Z. From human-computer interaction to human-AI 509 Interaction: new challenges and opportunities for enabling human-centred AI. ArXiv 510 Prepr ArXiv210505424. 2021;5. 511 27. Zhang Y, Liao QV, Bellamy RK. Effect of confidence and explanation on accuracy and 512 trust calibration in AI-assisted decision making. In: Proceedings of the 2020 conference 513 on fairness, accountability, and transparency. 2020. p. 295-305. 514 28. Cao S, Huang CM. Understanding User Reliance on AI in Assisted Decision-Making. 515 Proc ACM Hum-Comput Interact. 2022;6(CSCW2):1–23. 29. Ranji SR, Rennke S, Wachter RM. Computerised provider order entry combined with 516 517 clinical decision support systems to improve medication safety: a narrative review. BMJ 518 Qual Saf. 2014 Sep;23(9):773-80. 519 30. Zhang K, Wang H, Du J, Chu B, Arévalo AR, Kindle R, et al. An interpretable RL 520 framework for pre-deployment modelling in ICU hypotension management. Npj Digit 521 Med. 2022 Nov 18;5(1):1–10. 522 31. Crafting an intended purpose in the context of software as a medical device (SaMD) 523 [Internet], GOV.UK, [cited 2023 Mar 28], Available from: 524 https://www.gov.uk/government/publications/crafting-an-intended-purpose-in-the-525 context-of-software-as-a-medical-device-samd/crafting-an-intended-purpose-in-the-526 context-of-software-as-a-medical-device-samd 527 Azamfirei R, Kudchadkar SR, Fackler J. Large language models and the perils of their 528 hallucinations. Crit Care. 2023 Mar 21;27(1):120. 529 Quinonero-Candela J, Sugiyama M, Schwaighofer A, Lawrence ND. Dataset Shift in 33. 530 Machine Learning. MIT Press; 2022. 246 p. 531 34. Festor P, Luise G, Komorowski M, Faisal AA. Enabling risk-aware Reinforcement 532 Learning for medical interventions through uncertainty decomposition. ICML. 2021; 533 Trombley CM, Gulum MA, Ozen M. Evaluating Uncertainty-Based Deep Learning 35. 534 Explanations for Prostate Lesion Detection. MLHC. 2022; Shafti A, Derks V, Kay H, Faisal AA. The Response Shift Paradigm to Quantify Human 535 36. 536 Trust in AI Recommendations [Internet]. arXiv; 2022 [cited 2023 Jan 19]. Available

- 537 from: http://arxiv.org/abs/2202.08979
- 538 37. Harston JA, Faisal AA. Methods and Models of Eye-Tracking in Natural Environments. In: Eye Tracking: Background, Methods, and Applications. Springer; 2022. p. 49-68. 539
- 540 38. Gidlöf K, Wallin A, Dewhurst R, Holmgvist K. Using eye tracking to trace a cognitive
- 541 process: Gaze behaviour during decision making in a natural environment. J Eve Mov 542 Res. 2013;6(1).
- 543

544 **FIGURES**

545





546

Figure 1: Experimental design – A. Photo of the simulation suite with: (1) Bedside monitor 547 (2) AI screen (3) Participant (4) Bedside nurse (5) Patient mannequin (6) Intensive care unit 548 549 (ICU) bedside information chart. B. Experimental protocol diagram. C. Gaze-based attention 550 extraction pipeline: eye-tracking glasses, pupil camera view, a recorded field of view with 551 April tags (QR codes) and reconstructed data with fixation heatmaps on the different regions 552 of interest (ROIs).







555

Figure 2: Recruited cohort demographics – A. Distribution of intensive care experience.

556 B. Gender distribution. C. Proportion of physicians who had ever been involved in a research 557 project involving AI. This cohort covers the whole range of experience levels, is in line with 558 national gender ratios and contains both people who have and have not worked with AI.





560

561 Figure 3: Impact of AI recommendation safety status on clinician decisions, and gaze fixations on each ROI. - A. Bar chart of the proportion of stopped safe recommendations, 562

563 stopped unsafe recommendations and stopped or escalated unsafe recommendations. B. 564 Proportions of requests for senior help before seeing any recommendation and after having 565 seen a safe or an unsafe one. C. Number of gaze fixations on each ROI before revealing the

Al recommendation (i.e. there can be no fixations on the Al) **D**. Number of gaze fixations on each ROI after revealing the Al recommendation (when clinicians have already evaluated the non-Al information sources and so would be expected to look at these much less). *** p<0.0001, ** p<0.005, * p<0.05, *n.s.* not significant.

570





572 **Figure 4: Clinical practice variability** – Distribution of initial (i.e. pre Al reveal) vasopressor 573 (left) and fluid (right) prescriptions by physicians for each patient scenario.

574



575

576 **Figure 5: Shift analysis** – Vasopressors dose distribution before and after having seen a 577 safe or unsafe AI recommendation for two patient scenarios across all physicians (left) and 578 only those who did not ask for senior/second review (right). Unsafe AI recommendations do 579 not always influence the final decision. Physicians most influenced by unsafe AI

recommendations tend to ask for a second opinion, while those who do not ask for help are less influenced by unsafe recommendations.

Appendix A - Pre-experiment questionnaire

- How old are you?
- Gender?
- For how many years have you been working in ICU?
- Are you personally involved, or have experience, in AI research?
- Your opinions on Artificial Intelligence (AI) on a 5-point Likert scale ('Strongly disagree', 'Disagree', 'Neutral', 'Agree', 'Strongly agree')
 - Al will benefit society at large
 - Al will personally benefit me in my day to day life
 - AI will benefit the National Health Service (NHS)
 - Al will personally benefit my work as a clinician
 - I would be comfortable using a validated AI in areas of high clinical uncertainty, such as sepsis resuscitation
 - If we had strong evidence that a doctor assisted by AI was better than a doctor alone at treating sepsis, this AI should be used always and everywhere
 - Widespread use of AI for clinical decision making will lead to deskilling of human doctors
 - If doctors put too much trust in AI, they won't be able to detect when the AI fails, and it will lead to patient harm

Appendix B - Nurse challenge scripts

	If participant WOULD override unsafe AI suggestion	If participant would NOT override unsafe AI suggestion
Size of patient data	"But hasn't this AI seen thousands more patients than we have? Are you really sure you'd override it?"	"But how do we know that the AI has seen a patient like the one we've got here? Are you really sure you'd allow this suggestion to be acted on?"
New technology	"But what's the point of having new technology in the hospital if we aren't going to make the most of it to help our patients?"	"But do we really understand how this AI was designed or made though?"
Medicolegal implications	"But what if something goes wrong and the patient or their family see that we went against the AI? How protected or vulnerable would we be?"	"But what if something goes wrong and the patient or their family see that we followed a computer suggestion instead of our own judgement? How protected or vulnerable would we be?"

Appendix C - Patient scenarios

Patient 1 handover note for participants:

- 50M admitted 2hrs ago from ED with SOB. •
- PMHx: HTN, high cholesterol •
- Bedside TTE in ED: good bivent function, hyperdynamic. •
- CXR: left basal consolidation. COVID -ve. •
- ECG: sinus tachy •
- Admission obs from ED: HR 125, systolic low 70s, sats 76 on air •
- Given 3x 250ml boluses so far in ED and 1L so far in ICU •
- Stat co-amoxiclav and clarithromycin •
- Lac 3.7 in ED, UO 25ml over last 4 hrs .

Mannequin settings:

•	Heart r	ate:	113
•	Blood p	pressure:	78/42
•	Respira	atory rate:	38
•	Saturat	tions:	94 (on 5L via mask)
•	Tempe	rature:	38.9
•	Sounds	3	
	0	Heart:	Normal
	0	L lung:	Creps
	0	R lung:	Clear
•	Pulses	:	
	0	Central:	Full
	0	Peripheral:	50%

Speech: Short sentences, alert

Al actions:

- Al safe action .
 - Fluid: 900 ml/hr 0 Vasopressor: 0 mcg/kg/min 0
- Al unsafe action
 - 40 ml/hr 0 Fluid: Vasopressor: 0 mcg/kg/min 0

Justification:

Middle-aged man in septic shock secondary to community acquired pneumonia. Early in hospital course with low volume of fluid resuscitation thus far (given febrile and likely high insensible losses too). Oliguric and tachypneoic. Would be reasonable to trial more fluid prior to vasopressor start or to commence both simultaneously if concerned about risk of pulmonary oedema although no overt risk factors for this (i.e. no background history of poor cardiac function). Essentially ceasing resuscitation by low dose fluid and no norad would be dangerous.

Patient 2 handover note for participants:

- 84F admitted last night from ED with dysuria, presumed urosepsis. COVID -ve. •
- PMH: COPD (no admissions), HTN (2 agents), mild cognitive impairment •
- No bedside TTE performed •
- ECG: sinus •
- CXR: unremarkable •
- Still spiking, never tachycardic, systolic not yet above 90 •
- On tazocin + stat amikacin last night •
- Fluid balance +ve 3.5L since admission •
- Latest lac 0.7, UO 10-15 ml/hr last 4 hrs

Manneguin settings:

•	Heart rate:	67

- Blood pressure: 84/50 •
- Respiratory rate: 18
- Saturations: 95 (on 2L NC) . 37.8
- Temperature: .
- Sounds •
 - 0 Heart: Normal
 - Clear L lung: 0
 - 0 R lung: Clear
- Pulses:

0 0

- Central: Full
- Peripheral: 50%
- Speech: Confused, drowsy

AI actions:

AI safe action	
• Fluid:	70 ml/hr
• Vasopressor:	0.09 mcg/kg/min

- Al unsafe action
 - Fluid: 5 ml/hr • Vasopressor: 0.75 mcg/kg/min

Justification:

Elderly lady with septic shock secondary to gram negative bacteraemia from UTI. Normally hypertensive and oliguric. Yet to respond to reasonable volume of fluid resuscitation. Minimal oxygen requirement but elderly and underlying lung condition might make concern about iatrogenic volume overload more pressing. Lack of tachycardia might suggest beta blocker use or poor sympathetic drive. Vasopressor would be beneficial but probably only needs a small dose rather than the proposed unsafe dose which would be dangerous.

Patient 3 handover note for participants:

- 42F admitted 8d ago from ED with SOB. COVID +ve pneumonia. •
- PMH: T2DM (orals, HbA1C 50), BMI 41 •
- Admission bedside TTE unremarkable, nil since •
- I&V since admission, now onto PSV but new spikes last 24hrs, septic screen sent. •
- PSV 10/6 with sats 93 on FiO2 0.45. •
- Had 5 day tazocin course on admission, currently off antimicrobials •
- Fluid balance -250ml last 48 hrs •
- Latest lac 2.3, UO 60-70 ml/hr last 4 hrs •

Mannequin settings:

•	Heart rate:	106
•	Blood pressure:	90/58
•	Respiratory rate:	23

- Respiratory rate: •
- Saturations: 93 (on 45% O2 via ETT) •
- Temperature: 38.3 .
- Sounds .

0	Heart:	Normal

- 0 L lung: Creps
- Creps R lung: 0
- Pulses:

0	Central:	Full
0	Peripheral:	Full
Speed	ch:	Nil

Al actions:

AI safe	e action	
0	Fluid:	50 ml/hr
0	Vasopressor:	0.04 mcg/kg/min

Al unsafe action

0	Fluid:	100 ml/hr
0	Vasopressor:	0.54 mcg/kg/min

Justification:

Middle aged lady with sepsis secondary to likely ICU acquired infection (could be line related or ventilator-associated). Has been in ICU for over a week so likely to be fluid replete. SIRS positive but no overt evidence of profound shock (especially as on propofol sedation). Low dose norad around the current dose likely to be reasonable but excessive dose unnecessary. Is already on NG intake so excessive fluid probably unnecessary but some additional to counteract insensible losses from fever might be reasonable. High dose norad unnecessary and likely dangerous.

Patient 4 handover note for participants:

- 63M admitted 8 hrs ago from theatres post laparotomy for perforated colon 2ry to diverticular • disease.
- PMH: Diverticular disease, T2DM (diet controlled, HbA1C 45), HTN (1 agent), psoriasis •
- Bedside TTE: possible mild LV impairment. •
- Norad 0.34 (up from peak 0.21 in theatre) •
- Fluid balance +ve 6.5L last 12 hrs •
- Latest lac 5.8, UO 15ml over last 3 hrs •

Mannequin settings:

- Heart rate: 123 •
- 100/70 Blood pressure: •
- Respiratory rate: • 18
- Saturations: 96 (on 35% O2 via ETT) •

35.4

Clear

- Temperature:
- Sounds .
 - Normal 0 Heart:
 - L lung: Clear 0
 - 0 R lung:
- Pulses:

0	Central:	Full
0	Peripheral:	Full

- 0 Peripheral: Nil Speech:

Al actions:

Al safe action

0	Fluid:	236 ml/hr
0	Vasopressor:	0.38 mcg/kg/min

- Al unsafe action
 - 20 ml/hr Fluid: 0 0
 - 0 mcg/kg/min Vasopressor:

Justification:

Middle aged man with septic shock secondary to abdominal sepsis after perforated viscus. Hypertension noted as well as echo suggestive of LV impairment (even in a setting of likely hyperdynamic sepsis). Oliguric, high lactate and high norad dose already (with a rising trajectory) despite large volume positive fluid balance. Likely to need ongoing fluid resuscitation to compensate for ongoing third space losses as well as a possible trial of higher MAP target (given hypertensive normally) for renal perfusion to see if it improves oliguria. Complete cessation of vasopressor would be dangerous.

Patient 5 handover note for participants:

- 33F admitted last night from ED with SOB. COVID -ve. •
- PMH: Ex-IVDU, asthma (no admissions), cachectic •
- ECG: 1st degree HB, right axis •
- CXR: bilat congestion, ?pulmonary oedema vs. infection. •
- Bedside TTE: severe AR + MR, possible vegetations. •
- Norad 0.04 (up, started 4 hrs ago) •
- Fluid balance -250ml last 12 hrs •
- Latest lac 4.3, UO 40-50 ml/hr last few hours •

Mannequin settings:

•	Heart rate:	107
		400/00

- Blood pressure: 103/38
- Respiratory rate: 28 •
- Saturations: • 92 (on 4L NC)
- Temperature: 38.7 •
- Sounds •
 - Normal 0 Heart:
 - 0 L lung: Creps
 - Creps R lung: 0
- Pulses:

Speech:

0	Central:	Full
0	Peripheral:	Full

Full Short sentences but alert

Al actions:

Al safe	e action	
0	Fluid:	30 ml/hr
0	Vasopressor:	0.02 mcg/kg/min

- Al unsafe action
 - Fluid: 278 ml/hr Vasopressor: 0.47 mcg/kg/min 0

Justification:

Young lady with mixed septic and cardiogenic shock secondary to endocarditis. Already developing a rising oxygen requirement secondary to pulmonary oedema. Wide pulse pressure and severe valvular regurgitation would make high dose norad dangerous due to excessive afterload and worsening of pulmonary oedema (as would high dose fluid resuscitation). Urine output is reasonable and systolic not too bad despite MAP so overall a reduction in fluid volume would be reasonable while seeking cardiothoracic specialist opinion (i.e. definitive management).

Patient 6 handover note for participants:

- 29M admitted 8 hrs ago from ED for perineal cellulitis +/- nec fasc.
- CT scanner delay, aiming scan imminently, surgeons finishing prev emergency case
- PMH: T1DM (HbA1C 94), prev left big toe amputation
- ECG: sinus tachy
- CXR: clear (on admission)
- Bedside TTE: hyperdynamic LV
- Norad 0.14, started 3 hrs ago, rising
- Fluid balance +7.5L last 12 hrs
- Latest lac 8.3, UO 80-150 ml/hr last few hours

Mannequin settings:

- Heart rate: 132
- Blood pressure: 89/53
- Respiratory rate: 32
- Saturations: 90 (on 4L NC)
- Temperature:

Central:

Peripheral:

- Sounds
 - Heart: Normal
 - L lung: Creps
 - R lung: Creps
- Pulses:

0 0

Speech:

Full

39.2

- 0%
 - Groaning, uncomfortable, confused

Al actions:

.

- Al safe action • Fluid: 0 ml/hr • Vasopressor: 0.19 mcg/kg/min
- All unsafe action
 - Fluid: 377 ml/hr
 Vasopressor: 0.02 mcg/kg/min

Justification:

Young man with septic shock secondary to necrotising fasciitis. Severe tachycardia and shock with rising norad trajectory and high lactate. Urine output is good though. Worsening oxygen requirement, highly positive fluid balance and hyperdynamic heart likely to suggest an increase in norad to maintain MAP probably preferable to further fluid. Likely course of this patient will be exploration and debridement in theatre where they will receive further fluid in any case. Overall, reducing fluid at this stage and increasing norad more likely to be preferable. Sudden drop in norad to 0.02 likely to be dangerous.

Appendix D - Trial matrix

		De	cisio	n po	pint		Trial type	S	Safe				
Subject n°	1	2	3	4	5	6		U	Unsafe	e			
1	S	S	S	S	U	С		С	Challenged unsafe				
2	S	S	SUSC								_		
3	S	S	U	S	S	С	21	S	S	S	S	С	U
4	S	U	S	S	S	С	22	S	S	S	U	S	С
5	S	S	S	S	С	U	23	S	S	U	S	S	С
6	S	S	S	С	υ	S	24	S	U	S	S	S	С
7	S	S	U	S	С	S	25	S	S	S	S	С	U
8	S	U	S	S	С	S	26	S	S	S	U	С	S
9	S	S	S	U	S	С	27	S	S	U	S	С	S
10	S	S	S	С	U	S	28	S	U	S	S	С	S
11	S	S	U	С	S	S	29	S	S	S	С	S	U
12	S	U	S	С	S	S	30	S	S	S	С	U	S
13	S	S	С	S	S	U	31	S	S	U	С	S	S
14	S	S	С	S	U	S	32	S	U	S	С	S	S
15	S	S	С	U	S	S	33	S	S	С	S	S	υ
16	S	U	С	S	S	S	34	S	S	С	S	U	S
17	S	С	S	S	S	U	35	S	S	С	υ	S	S
18	S	С	S	S	U	S	36	S	U	С	S	S	S
19	S	С	S	U	S	S	37	S	С	S	S	S	U
20	S	С	U	S	S	S	38	S	С	S	S	U	S

Appendix E - Initial dose discrepancies discussion

Figure 4 in the main text shows the distribution of doses initially decided by subjects by drug and scenario. In light of the patient scenarios described above, we here propose a discussion of Figure 4.

Patient 1 was given more fluids than patient 2 likely because it has received more fluids so far. Patient 5 was given significantly less fluids than others, most likely because subjects wanted to avoid causing harm to a patient with heart sepsis and potentially damaged valves.



